{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:09:31Z","timestamp":1783652971898,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["code P2022ALA55"],"award-info":[{"award-number":["code P2022ALA55"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUP D53D23021540001"],"award-info":[{"award-number":["CUP D53D23021540001"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007065","name":"Universit\u00e0 degli Studi di Salerno","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007065","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The purpose of this study was to investigate multi-fluid spray drying as a formulation strategy to engineer inhalable microparticles containing levofloxacin and mucolytic agents, and to evaluate how formulation and process parameters influence particle properties, aerosol performance, and drug release under mucus-relevant conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Microparticles containing levofloxacin in combination with mucolytic agents were produced using a mini spray dryer equipped with a triple-fluid nozzle. Different compositions and particle architectures were obtained by varying formulation and excipient allocation. The resulting powders were characterized in terms of morphology, bulk, tapped and true density, aerodynamic performance, and\n                      <jats:italic>in vitro<\/jats:italic>\n                      drug release evaluated both in the absence and presence of a mucus layer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ambroxol showed greater suitability for spray drying than N-acetylcysteine, resulting in markedly higher process yields (up to 74%). The incorporation of L-leucine as a functional excipient reduced particle agglomeration and improved powder handling and aerosolization, with fine particle fractions exceeding 38% for leucine containing formulations. Drug release experiments demonstrated that spray drying altered release behaviour under diffusion limiting conditions imposed by a mucus layer compared to dissolution under sink conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, the results indicate that multi-fluid spray drying enables effective modulation of the physicochemical and aerodynamic properties of inhalable microparticles. This study provides mechanistic insight into how formulation composition and process design influence particle behaviour in mucus-relevant environments, supporting the use of this approach as a flexible platform for the development of inhalable formulations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11095-026-04103-6","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T20:07:14Z","timestamp":1776974834000},"page":"1517-1528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mucolytic Core\u2013Shell Particles to Boost Levofloxacin Penetration Through the Mucus Barrier in Cystic Fibrosis"],"prefix":"10.1007","volume":"43","author":[{"given":"Valentina","family":"Ruggiero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Larobina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"D\u2019Avino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Trofa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consiglia","family":"Tedesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Del Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4362-4388","authenticated-orcid":false,"given":"Paola","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"4103_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jcf.2009.04.005","volume":"8","author":"H Heijerman","year":"2009","unstructured":"Heijerman H, Westerman E, Conway S, Touw D. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2009;8:295\u2013315. https:\/\/doi.org\/10.1016\/j.jcf.2009.04.005.","journal-title":"J Cyst Fibros"},{"key":"4103_CR2","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.1021\/acsami.1c14975","volume":"14","author":"G Conte","year":"2022","unstructured":"Conte G, Costabile G, Baldassi D, Rondelli V, Bassi R, Colombo D, et al. Hybrid lipid\/polymer nanoparticles to tackle the cystic fibrosis mucus barrier in siRNA delivery to the lungs: does PEGylation make the difference? ACS Appl Mater Interfaces. 2022;14:7565\u201378. https:\/\/doi.org\/10.1021\/acsami.1c14975.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4103_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124182","volume":"657","author":"CT Dhege","year":"2024","unstructured":"Dhege CT, Kumar P, Choonara YE. Pulmonary drug delivery devices and nanosystems as potential treatment strategies for acute respiratory distress syndrome (ARDS). Int J Pharm. 2024;657:124182. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124182.","journal-title":"Int J Pharm"},{"key":"4103_CR4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40199-024-00520-3","volume":"32","author":"N Islam","year":"2024","unstructured":"Islam N, Suwandecha T, Srichana T. Dry powder inhaler design and particle technology in enhancing pulmonary drug deposition: challenges and future strategies. DARU J Pharm Sci. 2024;32:761\u201379. https:\/\/doi.org\/10.1007\/s40199-024-00520-3.","journal-title":"DARU J Pharm Sci"},{"key":"4103_CR5","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1053\/rmed.2000.0834","volume":"94","author":"J Littlewood","year":"2000","unstructured":"Littlewood J, Koch C, Lambert P, H\u00f8iby N, Elborn J, Conway S, et al. A ten year review of colomycin. Respir Med. 2000;94:632\u201340.","journal-title":"Respir Med"},{"key":"4103_CR6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","volume":"68","author":"A Schuster","year":"2013","unstructured":"Schuster A, Haliburn C, D\u00f6ring G, Goldman MH, Group, F.S. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax. 2013;68:344\u201350.","journal-title":"Thorax"},{"key":"4103_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/1753465817691239","volume":"11","author":"K Hamed","year":"2017","unstructured":"Hamed K, Debonnett L. Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence. Ther Adv Respir Dis. 2017;11:193\u2013209.","journal-title":"Ther Adv Respir Dis"},{"key":"4103_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10030338","volume":"10","author":"G Taccetti","year":"2021","unstructured":"Taccetti G, Francalanci M, Pizzamiglio G, Messore B, Carnovale V, Cimino G, et al. Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives. Antibiotics. 2021;10:338.","journal-title":"Antibiotics"},{"key":"4103_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4103\/0970-2113.63603","volume":"27","author":"P Gupta","year":"2010","unstructured":"Gupta P. Ambroxol-resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases. Lung India. 2010;27:46\u20138.","journal-title":"Lung India"},{"key":"4103_CR10","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/quinsair. Accessed 20 Dec 2025."},{"key":"4103_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/pharmaceutics12010055","volume":"12","author":"A Lechanteur","year":"2020","unstructured":"Lechanteur A, Evrard B. Influence of composition and spray-drying process parameters on carrier-free DPI properties and behaviors in the lung: a review. Pharmaceutics. 2020;12:55.","journal-title":"Pharmaceutics"},{"key":"4103_CR12","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.drudis.2021.04.009","volume":"26","author":"N Alhajj","year":"2021","unstructured":"Alhajj N, O\u2019Reilly NJ, Cathcart H. Leucine as an excipient in spray dried powder for inhalation. Drug Discov Today. 2021;26:2384\u201396. https:\/\/doi.org\/10.1016\/j.drudis.2021.04.009.","journal-title":"Drug Discov Today"},{"key":"4103_CR13","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1017\/S0007114509990663","volume":"102","author":"ML Stewart","year":"2009","unstructured":"Stewart ML, Slavin JL. Particle size and fraction of wheat bran influence short-chain fatty acid production in vitro. Br J Nutr. 2009;102:1404\u20137.","journal-title":"Br J Nutr"},{"key":"4103_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ejpb.2014.02.010","volume":"87","author":"P Del Gaudio","year":"2014","unstructured":"Del Gaudio P, Auriemma G, Russo P, Mencherini T, Campiglia P, Stigliani M, et al. Novel co-axial prilling technique for the development of core\u2013shell particles as delayed drug delivery systems. Eur J Pharm Biopharm. 2014;87:541\u20137.","journal-title":"Eur J Pharm Biopharm"},{"key":"4103_CR15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ejpb.2008.10.007","volume":"72","author":"F Sansone","year":"2009","unstructured":"Sansone F, Aquino RP, Del Gaudio P, Colombo P, Russo P. Physical characteristics and aerosol performance of naringin dry powders for pulmonary delivery prepared by spray-drying. Eur J Pharm Biopharm. 2009;72:206\u201313.","journal-title":"Eur J Pharm Biopharm"},{"key":"4103_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17020199","author":"Y Huang","year":"2025","unstructured":"Huang Y, Arte KS, Patil CD, Zhou Q, Qu L. Impact of co-spray drying with leucine or trileucine on aerosol performance, in vitro dissolution, and cellular uptake of colistin powder formulations for inhalation. Pharmaceutics. 2025. https:\/\/doi.org\/10.3390\/pharmaceutics17020199.","journal-title":"Pharmaceutics"},{"key":"4103_CR17","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1021\/acs.cgd.7b00764","volume":"17","author":"O Gyulai","year":"2017","unstructured":"Gyulai O, Szab\u00f3-R\u00e9v\u00e9sz P, Aigner Z. Comparison study of different spherical crystallization methods of Ambroxol Hydrochloride. Cryst Growth Des. 2017;17:5233\u201341. https:\/\/doi.org\/10.1021\/acs.cgd.7b00764.","journal-title":"Cryst Growth Des"},{"key":"4103_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1515\/amma-2017-0014","volume":"63","author":"N P\u00e1sztor","year":"2017","unstructured":"P\u00e1sztor N, R\u00e9dai E, Szab\u00f3 Z-I, Sipos E. Preparation and characterization of levofloxacin-loaded nanofibers as potential wound dressings. Acta Med Marisiensis. 2017;63:66\u20139.","journal-title":"Acta Med Marisiensis"},{"key":"4103_CR19","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3109\/10837450.2015.1086369","volume":"21","author":"E Ghasemian","year":"2016","unstructured":"Ghasemian E, Vatanara A, Rouini MR, Rouholamini Najafabadi A, Gilani K, Lavasani H, et al. Inhaled sildenafil nanocomposites: lung accumulation and pulmonary pharmacokinetics(). Pharm Dev Technol. 2016;21:961\u201371. https:\/\/doi.org\/10.3109\/10837450.2015.1086369.","journal-title":"Pharm Dev Technol"},{"key":"4103_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105340","volume":"92","author":"V Ruggiero","year":"2024","unstructured":"Ruggiero V, Aquino G, Del Gaudio P, Mencherini T, Tedesco C, Russo P. Development and characterization of nintedanib inhalable powders as a potential pulmonary fibrosis treatment. J Drug Deliv Sci Technol. 2024;92:105340. https:\/\/doi.org\/10.1016\/j.jddst.2024.105340.","journal-title":"J Drug Deliv Sci Technol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04103-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04103-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04103-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:30:30Z","timestamp":1781537430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04103-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4103"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04103-6","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}